Вилдегра is commonly used to address two primary therapeutic domains related to functional stability and systemic imbalance, specifically Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

For Erectile Dysfunction, the medicine is generally used to address symptom clusters that interfere with daily functioning, such as the inability to achieve or maintain an erection adequate for satisfactory sexual activity. It assists with maintaining functional stability, providing support that may help patients cope more steadily with these episodic functional challenges and contributes to easing the overall symptom load related to sexual health. For Pulmonary Arterial Hypertension, the medicine is considered relevant for managing this chronic condition where symptoms are related to systemic imbalance in the lungs. It is applied when supportive symptom management is appropriate, as it contributes to supporting physical capacity and helps ease the overall symptom burden during episodes of heightened discomfort during exertion.

“The medication is commonly used in clinical settings where functional support for both episodic sexual health challenges and chronic systemic vascular conditions is needed.”

Quick Fact: Support for Erectile Functional Impairment

Regulatory References

1. NIH MedlinePlus overview of Sildenafil

The official eligibility criteria for Вилдегра (sildenafil) are based on the patient’s health status, age, and concurrent use of certain medications, as specified in regulatory labeling.

Contraindicated Populations (Must Not Use)

Category	Population/Condition	Regulatory Basis
Concomitant Drug Use	Patients taking any form of organic nitrates or riociguat	Contraindicated (Risk of severe hypotension)
Acute Health Events	Recent history of stroke or myocardial infarction (heart attack)	Contraindicated (Safety not established)
Cardiovascular/Organ Status	Severe hepatic impairment, hypotension (BP <90/50 mmHg), or when sexual activity is inadvisable due to severe heart problems	Contraindicated (Safety not studied)
Prior History	History of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION)	Contraindicated

Age and Conditional Eligibility

The medicine is formally indicated only for adult men (ge 18 years of age); use by the pediatric population or women is not indicated.

Eligibility is restricted for certain populations where reduced drug clearance is expected:

• Severe Renal Impairment and Hepatic Impairment: A lower initial dose must be considered, as clearance is significantly reduced.
• Predisposition to Priapism (e.g., sickle cell anaemia) or Anatomical Deformation of the Penis (e.g., Peyronie's disease): Use requires special caution and careful medical assessment.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine by establishing absolute prohibitions (contraindications) when severe hypotension is a risk (e.g., with nitrates) or when the patient has acute cardiovascular instability. Eligibility for adult men with impaired organ function (kidneys, liver) is conditional, requiring consideration for dose adjustment due to altered drug clearance, ensuring a highly specific population-eligibility constraint.

The official regulatory profile for Вилдегра (Sildenafil) establishes several strict interaction patterns based on pharmacological class and metabolism.

Co-administration is contraindicated with Organic Nitrates and Nitric Oxide Donors in any form (regular or intermittent) due to the documented risk of severe pharmacodynamic potentiation and resulting hypotension. The same restriction applies to the Guanylate Cyclase Stimulator Riociguat for the same reason.

In terms of pharmacokinetic interactions, co-administration with potent CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) increases Sildenafil plasma exposure by reducing metabolic clearance. This necessitates a regulatory restriction: the maximum single dose must not exceed 25 mg within a 48 hour period when used with Ritonavir.

An additive vasodilatory effect is documented when Sildenafil is co-administered with Alpha-Blockers, which may result in symptomatic hypotension; this risk is most pronounced within four hours post-dosing. Furthermore, the official profile notes reduced Sildenafil clearance in patients with Severe Renal or Hepatic Impairment, requiring consideration of a reduced 25 mg starting dose to manage documented increased systemic exposure. Ingestion with a high-fat meal may officially delay the onset of activity by reducing the absorption rate.

Targeted Inhibition of the PDE5 Enzyme

The mechanism of Вилдегра's active ingredient, Sildenafil, involves its function as a selective Phosphodiesterase type 5 (PDE5) inhibitor. PDE5 is an enzyme whose natural role is the rapid breakdown (hydrolysis) of the critical intracellular messenger, cyclic guanosine monophosphate (cGMP). By inhibiting this enzyme, the drug prevents the deactivation of cGMP, thereby sustaining its concentration within specific smooth muscle cells.

---

Potentiation of the NO-cGMP Signaling Pathway

The drug's action is stimulus-dependent, potentiating the endogenous Nitric Oxide (NO) - cGMP pathway which is triggered by neural input. The sustained, elevated levels of cGMP directly activate processes that cause the relaxation of vascular smooth muscle in local arteries. This potentiation of the endogenous chemical cascade facilitates vasodilation (widening of blood vessels).

---

Facilitation of Increased Regional Blood Flow

The final step in this mechanistic sequence is the resulting adjustment of vascular smooth muscle tone and regional blood flow. By ensuring sustained smooth muscle relaxation, the drug supports increased arterial inflow and blood retention within the target tissue. This mechanistic cascade initiates the hydraulic events associated with the substance's known physiological activity.

General Administration Guidelines for Вилдегра (Sildenafil)

Standard protocols for using Sildenafil are based on its distinct applications: the intermittent, as-needed dosing for Erectile Dysfunction (ED) and the continuous, scheduled maintenance dosing for Pulmonary Arterial Hypertension (PAH). The medicine is delivered as an oral film-coated tablet.

Usage Condition	Erectile Dysfunction (ED) Dosing	Pulmonary Arterial Hypertension (PAH) Dosing
Recommended Starting Dose	50 mg (as needed)	20 mg three times a day (TID)
Dose Range / Maximum	25 mg to 100 mg maximum single dose	Can be titrated up to 80 mg TID
Timing & Frequency	Approximately one hour before sexual activity (range 30 min to 4 hrs). Maximum of once per day.	Doses taken approximately 4 to 6 hours apart.
Food Relationship	Can be taken with or without food; high-fat meals may delay the onset of effect.	Can be taken with or without food.

Administration Rules for Specific Populations

Standard prescribing protocols involve dose adjustments for certain patient groups where the body's clearance of the drug is reduced:

• Organ Impairment: A starting dose of 25 mg should be considered for patients with severe hepatic impairment (e.g., cirrhosis) or severe renal impairment (creatinine clearance < 30 mL/min).
• Co-Administration: A dose of 25 mg should be considered for patients receiving concomitant alpha-blockers or strong CYP3A4 inhibitors. When taken with Ritonavir, the maximum dose must not exceed 25 mg within a 48-hour period.
• Pediatric Use: Sildenafil tablets for ED are not indicated for individuals under 18 years of age.

These guidelines define the standardized administration protocols to ensure use aligns with established clinical documentation.

Research Evidence / Overview of Studies for Вилдегра (Sildenafil)

---

Evidence for Use in Erectile Dysfunction

The research base for Вилдегра (Sildenafil) in the context of male sexual function is founded on numerous short-term, parallel-group, Randomized Controlled Trials (RCTs), where Sildenafil was evaluated against a control group. These studies were applied in research contexts involving men experiencing functional limitations related to achieving or maintaining an erection. Researchers primarily measured functional outcomes using standardized instruments, such as the International Index of Erectile Function (IIEF) score, and recorded patient-reported outcomes describing perceived discomfort or successful attempts at sexual activity.

Studies report how symptoms evolved in the observed populations by tracking these standardized scores over defined time intervals, typically ranging from 4 to 12 weeks. Findings describe patterns observed in the studies related to changes in these measured functional outcomes in the Sildenafil group compared to a control group. This evidence contributes to understanding symptom patterns and perceived discomfort in conditions marked by functional limitations.

---

Evidence for Use in Pulmonary Arterial Hypertension

This part outlines the clinical study programs related to conditions involving chronic systemic vascular challenges in the lungs, describing the functional outcomes (like the 6-Minute Walk Distance) and major clinical events examined in pivotal trials.

Sildenafil was studied for its role in conditions involving chronic systemic vascular challenges in the lungs, a condition associated with acute or disruptive episodes. The evidence is derived from pivotal multicenter RCTs, where Sildenafil was evaluated against a control group over study periods typically lasting 12 to 16 weeks. The research examined outcomes related to systemic or functional imbalance by focusing on functional capacity. This was primarily measured by the 6-Minute Walk Distance (6MWD), a test used in observational settings evaluating daily-life functioning and activity level.

---

Key Limitations and Areas of Uncertainty in the Research

Official regulatory and scientific reviews acknowledge several limitations and areas where certainty remains low regarding the research evidence for Sildenafil. The most significant area of uncertainty relates to the pediatric long-term safety for the PAH indication, where findings were mixed, and subsequent regulatory actions were taken due to the patterns observed at higher doses. Across both indications, the evidence quality varies across studies, and some earlier trials had relatively limited comparative evidence against other available treatments in the same class. Additionally, while functional outcomes are commonly measured, there is limited information for long-term outcomes that fully characterize the long-term changes observed in research beyond the periods described in the extension studies.

Common questions about Вилдегра (FAQ)

Q: What is Вилдегра (Vildegra) used for?

A: Вилдегра is indicated for the treatment of erectile dysfunction in adult males. The medication is classified as a phosphodiesterase type 5 (PDE5) inhibitor.

Q: How does Вилдегра work?

A: Вилдегра's mechanism involves inhibiting the PDE5 enzyme, which is present in the corpus cavernosum of the penis. This action is associated with increasing blood flow to the penis, which may assist in achieving and maintaining an erection during sexual stimulation.

Q: How effective is Вилдегра?

A: Clinical trials have observed that Вилдегра may assist in the ability of men with erectile dysfunction to achieve an erection sufficient for sexual activity. The observed response can vary among individuals, and evidence suggests a higher response rate compared to placebo in studied populations.

Q: Can I take Вилдегра with food?

A: The absorption of Вилдегра may be affected by consuming a high-fat meal. This may be associated with a delayed onset of action.

Q: Is Вилдегра safe?

A: Clinical studies have reported common side effects that are generally mild and temporary. Like all medications, it carries potential risks. Your healthcare provider is the best source of information regarding its suitability and safety profile based on your personal medical history.

Storage and Disposal Conditions for Vildegra (Sildenafil)

Vildegra tablets must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept away from excess heat and moisture, and must not be frozen.

The product must remain in its tightly closed original container and be stored out of the reach of children and pets to prevent accidental ingestion.

Disposal Instructions

Official disposal guidelines recommend using a drug take-back program for unused or expired Vildegra. The medication is not included on the list of products recommended for flushing down the toilet. If a take-back option is unavailable, the uncrushed tablets should be mixed with an unappealing substance, placed in a sealed bag, and discarded in household trash. All personal information must be removed from the label before disposal.